Mark T. Dransfield

Active 1985–2025

161
Papers
19,234
Citations
77
h-index
149
i10-index

Citations

Citations per year for Mark T. Dransfield1975: 2 citations1984: 1 citations1986: 1 citations1987: 2 citations1988: 3 citations1989: 3 citations1990: 2 citations1991: 5 citations1992: 6 citations1993: 1 citations1994: 1 citations1996: 1 citations1997: 1 citations1998: 1 citations1999: 1 citations2002: 1 citations2004: 1 citations2006: 2 citations2007: 5 citations2008: 4 citations2009: 24 citations2010: 27 citations2011: 24 citations2012: 31 citations2013: 81 citations2014: 103 citations2015: 124 citations2016: 152 citations2017: 155 citations2018: 165 citations2019: 595 citations2020: 756 citations2021: 813 citations2022: 650 citations2023: 669 citations2024: 1,096 citations2025: 424 citations2026: 10 citations1976–1983: no citations, so these years are not shown1985: no citations, so this year is not shown1995: no citations, so this year is not shown2000–2001: no citations, so these years are not shown2003: no citations, so this year is not shown2005: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,717 citing papers, 23.5% of this breakdownUnited Kingdom: 822 citing papers, 11.2% of this breakdownChina: 654 citing papers, 8.9% of this breakdownCanada: 411 citing papers, 5.6% of this breakdownGermany: 346 citing papers, 4.7% of this breakdownSpain: 306 citing papers, 4.2% of this breakdownItaly: 300 citing papers, 4.1% of this breakdownNetherlands: 274 citing papers, 3.8% of this breakdownAustralia: 232 citing papers, 3.2% of this breakdownFrance: 187 citing papers, 2.6% of this breakdownSweden: 168 citing papers, 2.3% of this breakdownJapan: 163 citing papers, 2.2% of this breakdown
0%23.5%Other 23.7%

Fields

  • Medicine79.9%
  • Biochemistry, Genetics and Molecular Biology10%
  • Immunology and Microbiology2.2%
  • Environmental Science1.7%
  • Health Professions1.2%
  • Engineering1.2%
  • Other3.8%

Topics

  • Chronic Obstructive Pulmonary Disease (COPD) Research20.3%
  • Asthma and respiratory diseases8.2%
  • Respiratory Support and Mechanisms6%
  • Respiratory and Cough-Related Research3.4%
  • Inhalation and Respiratory Drug Delivery2.6%
  • Delphi Technique in Research2.3%
  • Other57.2%

Coauthors

All papers

Open in search
  1. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2022 cited by 650

  2. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,262

  3. Activated PMN Exosomes: Pathogenic Entities Causing Matrix Destruction and Disease in the Lung

    Authors: , , , , , , , , , , , , , , , , , , , - Cell 2019 cited by 457

  4. COPD and multimorbidity: recognising and addressing a syndemic occurrence

    Authors: , , , , , , , , , , , , - The Lancet Respiratory Medicine 2023 cited by 249

  5. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial

    Authors: , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2018 cited by 363

  6. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in US Adults

    Authors: , , , , , , , , , , , , , , , , , , - JAMA 2021 cited by 281

  7. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and Hypoxemia in Smokers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen P. Peters, Joyce Schroeder, Prescott G. Woodruff, John V. Fahy - American Journal of Respiratory and Critical Care Medicine 2020 cited by 179

  8. Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease

    Authors: , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2016 cited by 359

  9. Azithromycin for Prevention of Exacerbations of COPD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 1,207

  10. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2020 cited by 193

  11. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George R. Washko, J. Michael Wells, Chris H. Wendt, Robert A. Wise, Edwin K. Silverman, James D. Crapo, Russell P. Bowler, MeiLan K. Han - American Journal of Respiratory and Critical Care Medicine 2016 cited by 390

  12. openalex_id:w4225837250

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , cited by 130

  13. Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial

    Authors: , , , , , , , , , , , , - Journal of the American Heart Association 2022 cited by 79

  14. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

    Authors: , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2020 cited by 251

  15. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Respiratory Medicine 2019 cited by 240

  16. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality

    Authors: , , , , , , , , , , , , , , - JAMA 2019 cited by 212

  17. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life

    Authors: , , , , , , - European Journal of Internal Medicine 2020 cited by 207

  18. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - American Journal of Respiratory and Critical Care Medicine 2018 cited by 434

  19. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Russell P. Bowler, Elizabeth E. Carretta, Stephanie A. Christenson, Alejandro P Comellas, Christopher B. Cooper, David Couper, Gerard J. Criner, Ronald G. Crystal, Jeffrey L. Curtis, Claire M. Doerschuk, Mark T. Dransfield, Christine M. Freeman, MeiLan K. Han, Nadia N. Hansel, Annette T. Hastie, Eric A. Hoffman, Robert J. Kaner, Richard E. Kanner, Eric C. Kleerup, Jerry A. Krishnan, Lisa M. LaVange, Stephen C. Lazarus, Fernando J. Martínez, Deborah A. Meyers, John D. Newell, Elizabeth C. Oelsner, Wanda K. O’Neal, Robert Paine, Nirupama Putcha, Stephen I. Rennard, Donald P. Tashkin, Mary Beth Scholand, J. Michael Wells, Robert A. Wise, Prescott G. Woodruff - The Lancet Respiratory Medicine 2017 cited by 318

  20. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

    Authors: , , , , - The Lancet Respiratory Medicine 2015 cited by 733

  21. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen R. Wisniewski, Frank C. Sciurba, Prescott G. Woodruff - New England Journal of Medicine 2022 cited by 99

  22. Pulmonary Arterial Enlargement and Acute Exacerbations of COPD

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 492

  23. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elizabeth E. Carretta, Stephanie A. Christenson, Alejandro P Comellas, Christopher B. Cooper, David Couper, Gerard J. Criner, Ronald G. Crystal, Jeffrey L. Curtis, Claire M. Doerschuk, Mark T. Dransfield, Christine M. Freeman, MeiLan K. Han, Nadia N. Hansel, Annette T. Hastie, Eric A. Hoffman, Robert J. Kaner, Richard E. Kanner, Eric C. Kleerup, Jerry A. Krishnan, Lisa M. LaVange, Stephen C. Lazarus, Fernando J. Martínez, Deborah A. Meyers, John D. Newell, Elizabeth C. Oelsner, Wanda K. O’Neal, Robert Paine, Nirupama Putcha, Stephen I. Rennard, Donald P. Tashkin, Mary Beth Scholand, J. Michael Wells, Robert A. Wise, Prescott G. Woodruff - The Lancet Respiratory Medicine 2017 cited by 317

  24. Metoprolol for the Prevention of Acute Exacerbations of COPD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeremy A. Weingarten, J. Michael Wells, Elizabeth Westfall, Stephen C. Lazarus, John E. Connett - New England Journal of Medicine 2019 cited by 178